CL2011000999A1 - Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr. - Google Patents

Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr.

Info

Publication number
CL2011000999A1
CL2011000999A1 CL2011000999A CL2011000999A CL2011000999A1 CL 2011000999 A1 CL2011000999 A1 CL 2011000999A1 CL 2011000999 A CL2011000999 A CL 2011000999A CL 2011000999 A CL2011000999 A CL 2011000999A CL 2011000999 A1 CL2011000999 A1 CL 2011000999A1
Authority
CL
Chile
Prior art keywords
vsr
encodes
induce
nucleic acid
acid molecule
Prior art date
Application number
CL2011000999A
Other languages
English (en)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2011000999A1 publication Critical patent/CL2011000999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Virus sincicial respiratorio (VSR) vivo atenuado; molécula de ácido nucleico que lo codifica; célula recombinante; composición inmunogénica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infección por VSR.
CL2011000999A 2008-11-05 2011-05-04 Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr. CL2011000999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
CL2011000999A1 true CL2011000999A1 (es) 2012-07-20

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000999A CL2011000999A1 (es) 2008-11-05 2011-05-04 Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr.

Country Status (19)

Country Link
US (1) US9011876B2 (es)
EP (1) EP2346990B1 (es)
JP (2) JP5016731B2 (es)
KR (1) KR20110063863A (es)
CN (1) CN102272295A (es)
AU (1) AU2009311287C1 (es)
BR (1) BRPI0921424A2 (es)
CA (1) CA2742086A1 (es)
CL (1) CL2011000999A1 (es)
CO (1) CO6362047A2 (es)
EC (1) ECSP11011033A (es)
IL (1) IL212437A0 (es)
MA (1) MA32878B1 (es)
MX (1) MX2011004719A (es)
PE (1) PE20110394A1 (es)
RU (1) RU2011122615A (es)
TN (1) TN2011000182A1 (es)
WO (1) WO2010053883A1 (es)
ZA (1) ZA201103259B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053883A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
WO2013026054A2 (en) * 2011-08-18 2013-02-21 Axella Solutions, Llc Production of infectious rna viruses in yeast
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
CA2900713A1 (en) * 2013-02-08 2014-08-14 Steffen Mueller Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
JP6506249B2 (ja) * 2013-03-14 2019-04-24 エモリー ユニバーシティー サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2015057540A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
US10947512B2 (en) * 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods
BR112018008708A2 (pt) 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CA3075990A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0917592A4 (en) 1996-04-04 2002-04-24 Univ Michigan REDUCED RSV
AU767193B2 (en) 1998-03-26 2003-11-06 Wyeth Holdings Corporation Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B
EP1287152B1 (en) 1999-07-09 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Human-bovine chimeric respiratory syncytial virus vaccines
EP1572108A4 (en) 2002-09-27 2008-09-17 Medimmune Vaccines Inc FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
AU2004226369A1 (en) * 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
JPWO2008096811A1 (ja) * 2007-02-07 2010-05-27 ディナベック株式会社 弱毒化マイナス鎖ｒｎａウイルス
WO2010053883A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus

Also Published As

Publication number Publication date
MA32878B1 (fr) 2011-12-01
EP2346990B1 (en) 2016-01-06
JP2012507302A (ja) 2012-03-29
RU2011122615A (ru) 2012-12-20
JP2011250798A (ja) 2011-12-15
CA2742086A1 (en) 2010-05-14
TN2011000182A1 (en) 2012-12-17
AU2009311287A1 (en) 2010-05-14
CO6362047A2 (es) 2012-01-20
PE20110394A1 (es) 2011-06-22
WO2010053883A1 (en) 2010-05-14
AU2009311287B2 (en) 2013-02-07
BRPI0921424A2 (pt) 2016-01-05
US9011876B2 (en) 2015-04-21
KR20110063863A (ko) 2011-06-14
MX2011004719A (es) 2011-05-31
ZA201103259B (en) 2012-01-25
CN102272295A (zh) 2011-12-07
EP2346990A1 (en) 2011-07-27
JP5743794B2 (ja) 2015-07-01
AU2009311287C1 (en) 2015-02-19
IL212437A0 (en) 2011-06-30
ECSP11011033A (es) 2011-12-30
JP5016731B2 (ja) 2012-09-05
US20110212130A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
CL2011000999A1 (es) Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr.
EA201270063A1 (ru) Рекомбинантные антигены pcb
MX358836B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
MX2011011505A (es) Vacuna neumococica y usos de la misma.
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
EA201070794A1 (ru) Рекомбинантные антигены rsv
BR112012003064A2 (pt) anticorpos contra vírus sincicial respiratório (rsv) humano e métodos de uso
ME01199B (me) Nove kompozicije adjuvanta
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
WO2010053610A3 (en) Stable anthrax vaccine formulations
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
ZA201101552B (en) Composition comprising chitosan for ocular administration of vaccine(s) to avians
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
WO2012135701A3 (en) Compositions and methods for the detection of anaplasma platys
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
ATE457997T1 (de) Impfstoff gegen burkholderia-infektionen
UA110505C2 (ru) Імуногенні композиції bordetella bronchiseptica
MY172788A (en) Influenza vaccines
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren